Health hazard evaluation report HETA 90-390-2065, MHETA 86-012-2065 : R.T. Vanderbilt Company, Gouverneur, New York /

Cover title.

The economic well-being of Social Security beneficiaries, with an emphasis on divorced beneficiaries /

"December 1997."

Economic models of migration : review of the literature and some new evidence /

ASPER/PUR-76/3410/A

Economic impacts of a particular public service employment program /

Cover title.

Economic considerations for manpower revenue sharing /

Available from the National Technical Information Service, Springfield, Va.

The economic benefits from manpower training programs /

Photocopy.

Economic incentives and occupational safety /

Cover title.

Pilot project extension for economic development in Lowell, Massachusetts model city neighborhood, September 7, 1970 to February 15, 1972 : a terminal report /

Technical Assistance Grant Project, no. 01-6109132-1.

Policy evaluation with travel behavior models : methodological issues and case studies.

Mode of access: Internet.

The national evaluation of the Pilot Cities Program : a team approach to improving local criminal justice systems /

Issued November 1975.

Qualified Areas under the Public Works and Economic Development Act of 1965, as Amended, Public Law 89-136

Title Varies: Qualified Areas under the Public Works and Economic Development Act of 1965, Public Law 89-136; Areas Eligible for Financial Assistance Designated under the Public Works and Economic Development Act of 1965; Qualified Areas, Criteria and Data under the Public Works and Economic Development Act of 1965 Public Law 89-136

Evaluation forum /

"A review journal for employment and training professionals focusing on policy analysis and evaluation research in education, occupational training, work and welfare, and economic development."

Evaluation of the Feasibility of a Yoga and Mindfulness-Based Mental Health Intervention for Latina Immigrant Mothers

Thesis (Master's)--University of Washington, 2016-06

Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations"

Current pharmacotherapies for psychiatric disorders are generally incompletely effective. Many patients do not respond well or suffer adverse reactions to these drugs, which can result in poor patient compliance and poor treatment outcome. Adverse drug reactions and non-response are likely to be influenced by genetic polymorphisms. Pharmacogenetics holds some promise for improving the treatment of mood disorders by utilising information about genetic polymorphisms to match patients to the drug therapy that is the most effective with the fewest side effects. Pharmacogenomics promises to facilitate the development of new drugs for treatment. However, these technologies raise many ethical, economic and regulatory issues that need to be addressed before they can be integrated into psychiatry, and medicine more generally. We discuss ethical and policy issues arising from pharmacogenetic testing and pharmacogenomics research, such as informed consent, privacy and confidentiality, research on vulnerable persons and discrimination; and economic viability of pharmacogenetics and pharmacogenomics. We conclude with recommendations for the regulation and distribution of pharmacogenetic testing services and pharmacogenomic drugs.